Q1 EPS Estimate for PMV Pharmaceuticals Increased by Analyst

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) – Stock analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for shares of PMV Pharmaceuticals in a research note issued to investors on Wednesday, November 12th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.38) for the quarter, up from their prior forecast of ($0.41). The consensus estimate for PMV Pharmaceuticals’ current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for PMV Pharmaceuticals’ Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.65) EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of PMV Pharmaceuticals in a report on Monday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.00.

PMV Pharmaceuticals Stock Down 1.4%

PMVP stock opened at $1.40 on Monday. PMV Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $1.84. The business has a 50-day simple moving average of $1.38 and a 200 day simple moving average of $1.27. The company has a market cap of $74.50 million, a PE ratio of -0.88 and a beta of 1.54.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its earnings results on Wednesday, November 12th. The company reported ($0.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.40).

Insider Activity

In other news, major shareholder Orbimed Advisors Llc sold 1,000,000 shares of the company’s stock in a transaction on Thursday, October 23rd. The shares were sold at an average price of $1.52, for a total transaction of $1,520,000.00. Following the completion of the transaction, the insider directly owned 4,975,291 shares in the company, valued at approximately $7,562,442.32. This represents a 16.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On PMV Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Shay Capital LLC bought a new position in PMV Pharmaceuticals in the second quarter valued at about $26,000. Algert Global LLC acquired a new position in shares of PMV Pharmaceuticals in the third quarter valued at approximately $87,000. Jacobs Levy Equity Management Inc. bought a new position in PMV Pharmaceuticals in the 3rd quarter valued at approximately $96,000. PNC Financial Services Group Inc. boosted its position in PMV Pharmaceuticals by 16.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 71,006 shares of the company’s stock worth $99,000 after buying an additional 10,186 shares during the period. Finally, Bank of America Corp DE grew its holdings in PMV Pharmaceuticals by 457.5% during the 3rd quarter. Bank of America Corp DE now owns 162,496 shares of the company’s stock worth $227,000 after acquiring an additional 133,349 shares during the last quarter. Institutional investors own 90.20% of the company’s stock.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.